Chinese people's concerns about quality of locally made drugs are creating an opportunity for US firms says Gov

By Gareth Macdonald contact

- Last updated on GMT


Related tags: United states, Pharmacology

Chinese patients’ concerns about the quality of locally made drugs are an opportunity for US manufacturers to increase market share according to the US-China Economic and Security Review Commission.

The Commission – which reports to Congress on the national security implications of trade between the two countries – made the suggestion in a report​ this week also citing analysis​ by the US Department of Commerce.

Barriers to entry

The authors explained that although drugs are the US’ second largest and second fastest growing export to China – the value of pharmaceutical shipments increased from $402m in 2007 to $2.2bn in 2016 – the country still accounts for a relatively small amount of US sales.

In 2016 China was the second-largest pharmaceutical market globally, but only the ninth-largest export market for the United States, accounting for 4 percent of U.S. pharmaceutical preparation exports​” they said.

The authors attributed the disparity to barriers to entry that hamper US firms.

China uses an asynchronous review process to approve foreign pharmaceutical products that requires safety trials of foreign drugs to be at an advanced stage in other countries before Chinese regulators begin their own review process.

This significantly slows the introduction of new foreign drugs into China’s market, essentially doubling review times for foreign pharmaceuticals​” they said, adding that in some cases US drugs have been held up by as much as seven years.

Other barriers include the requirement that drugs are tested in China (a workaround for which was introduced in October​), the chronic shortage of Chinese regulatory staff as well as shortcomings in the country’s IP system.


Despite these hurdles, the authors suggest there are opportunities for US drug and active pharmaceutical ingredient (API) firms in China.

Chinese consumers may prefer US pharmaceutical products due to concerns over the quality of domestic drugs. China has been a prolific source of counterfeit and defective medicine​” according to the authors.

They cite the seizure of tainted gel capsules in 2012 ​as an example of issues that have damaged the reputation of China’s drug industry in China, also pointing to its reputation as a source for fake products as another factor.

According to the Office of the United States Trade Representative, in 2016, 90 percent of all counterfeit pharmaceuticals seized at the U.S. border were from China, Hong Kong, India, or Singapore.

Quality concerns may boost US pharmaceutical sales to China​” according to the Commission.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more